MAPT and Alzheimer disease: Multiple lines of evidence have indicated that the modalities that can dampen hippocampal Aβ42 and p-tau neurotoxic signals and curb glutaminergic neurotransmission are associated with favorable attenuation of AD and associated behavioral deficits [27,35].